MADRIGAL PHARMACEUTICALS INC. - COMMON STOCK

269.82

15-January-25 12:23:35

15 minutes delayed

Stocks

-4.30

-1.57%

Today's range

266.44 - 282.05

ISIN

N/A

Source

NASDAQ

Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences

01 Jun 2023 07:00:02 By Nasdaq GlobeNewswire
Madrigal Pharmaceuticals to Participate in the JMP Securities Life Sciences Conference

11 May 2023 07:00:02 By Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Provides Corporate Updates and Reports First Quarter 2023 Financial Results

09 May 2023 07:00:02 By Nasdaq GlobeNewswire
Madrigal Receives Breakthrough Therapy Designation from FDA for Resmetirom and Completes Enrollment of the Phase 3 MAESTRO-NASH Biopsy Trial

18 Apr 2023 07:00:01 By Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Provides Corporate Updates and Reports 2022 Fourth Quarter and Full Year Financial Results

23 Feb 2023 07:00:02 By Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

08 Feb 2023 07:00:01 By Nasdaq GlobeNewswire
Madrigal Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH with Liver Fibrosis

06 Jan 2023 07:00:00 By Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Announces $300+ Million in Financing Events to Advance Resmetirom Program

21 Dec 2022 15:15:14 By Nasdaq GlobeNewswire
Madrigal Announces Positive Topline Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH and Liver Fibrosis

19 Dec 2022 06:00:00 By Nasdaq GlobeNewswire
Madrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NASH Study of Resmetirom on Monday, December 19th

18 Dec 2022 15:00:00 By Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Provides an Overview of Upcoming Resmetirom Data Presentations and Reports 2022 Third Quarter Financial Results

03 Nov 2022 07:00:03 By Nasdaq GlobeNewswire
Madrigal Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

07 Sep 2022 07:00:04 By Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Initiates the MAESTRO-NASH Outcomes Study Evaluating Resmetirom for the Treatment of Patients with Compensated NASH Cirrhosis

31 Aug 2022 07:00:02 By Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 Second Quarter Financial Results

04 Aug 2022 07:00:08 By Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL’s International Liver Congress™

25 Jun 2022 08:00:00 By Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Supports International NASH Day on June 9

06 Jun 2022 07:00:01 By Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

02 Jun 2022 07:00:03 By Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences

17 May 2022 07:00:01 By Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 First Quarter Financial Results

09 May 2022 05:30:00 By Nasdaq GlobeNewswire
Madrigal Pharmaceuticals to Announce First Quarter 2022 Financial Results and Provide Clinical and Business Updates on May 9

28 Apr 2022 07:00:02 By Nasdaq GlobeNewswire

<<
<
1
2
3
4
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.